Saturday 17 October 2026
Export VIR’s income statement to Excel — free account
Vir Biotechnology, Inc.
Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.
9.96
0.51
−4.87%
Follow VIR
Vir Biotechnology, Inc. (VIR) P/E ratio
Vir Biotechnology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 10.4× (December 2021) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2025 | 0.0× | — |
| FY2024 | 0.0× | — |
| FY2023 | 0.0× | — |
| FY2022 | 6.4× | (38.81%) |
| FY2021 | 10.4× | — |
| FY2020 | 0.0× | — |
| FY2019 | 0.0× | — |
| FY2018 | 0.0× | — |
| FY2017 | 0.0× | — |
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
| Sep 2025 | 0.0× | — |
| 27 more quarters | Free account |
Against its own ten years
Low 0.0×
High 10.4×
Ten-year median
0.0×
Current reading's percentile
82
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| MRVI Maravai LifeSciences Holdings, Inc. compare | n/m |
| PVLA Palvella Therapeutics, Inc. compare | n/m |
| TRVI Trevi Therapeutics, Inc. compare | n/m |
| MESO Mesoblast Limited compare | n/m |
| BHVN Biohaven Ltd. compare | n/m |
| SEPN Septerna, Inc. compare | n/m |
| URGN Urogen Pharma compare | n/m |
| VIR Vir Biotechnology, Inc. | n/m |
| XNCR Xencor, Inc. compare | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)